The global secondary progressive multiple sclerosis drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Secondary progressive MS (SPMS) is a form of MS that occurs after relapsing-remitting MS. The disease varies across individuals and does not occur in all the patients who priorly have RRMS. The major factor contributing to the growth of the market is the increasing prevalence of the disease across the globe.
According to the National Multiple Sclerosis Society (NMSS), an estimated 50% of patients who are diagnosed with relapsing-remitting MS (RRMS) would transition to secondary-progressive MS (SPMS) within 10 years. Additionally, within 25 years, 90% of patients who are diagnosed with relapsing-remitting MS (RRMS) would evolve to secondary-progressive MS (SPMS). Hence, the rising prevalence of the disease is driving the demand for secondary progressive multiple sclerosis drugs.
To Request a Sample of our Report on Secondary Progressive Multiple Sclerosis Drug Market: https://www.omrglobal.com/request-sample/secondary-progressive-multiple-sclerosis-drug-market
Some major players operating in the market include Actelion Ltd., Biogen Inc., and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in March 2019, Novartis announced the approval of Mayzent (siponimod) from the FDA. It is an oral drug used for the treatment of relapsing forms of multiple sclerosis, including secondary progressive multiple sclerosis (SPMS) with active disease, relapsing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS) in adults.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Actelion Ltd., Biogen Inc., and Novartis International AG, among others.
(Get 15% Discount on Buying this Report)
A full Report of Secondary Progressive Multiple Sclerosis Drug Market is Available @ https://www.omrglobal.com/industry-reports/secondary-progressive-multiple-sclerosis-drug-market
Global Secondary Progressive Multiple Sclerosis Drug Market Report by Segment
By Type
- Inebilizumab
- GLX-1112
- DC-TAB
- Etomoxir
- IB-MS
- Others
By Application
- Hospital
- Clinic
- Others
Global Secondary Progressive Multiple Sclerosis Drug Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
